Kailera Therapeutics (KLRA) Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum summary

Market landscape and opportunity

• Obesity treatment rates remain low globally, with significant unmet needs and a vast patient population still to be addressed.

• Market pricing has evolved, with intentional price reductions by incumbents to unlock greater volume and value.

• Medicare expansion is rapidly increasing access, setting a pricing floor and driving broader coverage.

• Self-pay remains significant but is not sustainable for most; broad coverage is essential for long-term value.

• New entrants must differentiate beyond price, as the market will favor innovation and outcomes.

Pipeline and differentiation strategy

• Lead asset ribupatide is a dual agonist designed for superior efficacy and tolerability, with both injectable and oral forms advancing to phase III.

• Oral ribupatide shows promising tolerability, with low vomiting rates, potentially improving patient initiation and adherence.

• Differentiation focuses on clinical profile, not price, with plans to offer seamless switching between oral and injectable forms.

• The company leverages learnings from analog markets like statins, emphasizing the need for both strong data and commercial execution.

• China-derived data aids investor confidence and clinical design, but commercial claims will rely on global phase III results.

Commercial strategy and execution

• Early commercial leadership enables integration of market needs into clinical development and strategic planning.

• Brand foundations, market access, and enterprise readiness are prioritized ahead of tactical sales force build-out.

• Commercial approach will combine traditional HCP and consumer promotion with partnerships in telehealth and direct-to-employer channels.

• Capital allocation currently supports both clinical and commercial build, with scaling planned post-2028 as risk decreases.

• Focus and speed are advantages of the biotech model, allowing for nimble decision-making and targeted investment.